natgillin/translations-raw huggingface dataset:
The potential risk associated with retreatment with LEMTRADA following the occurrence of nephropathies is unknown.
Možno tveganje, povezano s ponovnim zdravljenjem z zdravilom LEMTRADA po pojavu nefropatij, ni znano.
The potential risk of an immune complex-mediated type III hypersensitivity reaction due to the formation of antibodies directed against Host Related Impurities (HRI).
morebitno tveganje preobčutljivostne reakcije tipa III, povzročene z imunskimi kompleksi, zaradi tvorbe protiteles proti nečistotam, povezanim z gostiteljem (HRI).
The potential risk of apnoea and the need for respiratory monitoring for 48-72h should be considered when administering the primary immunisation series to very premature infants (born ≤ 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity.
Med primarnim zaporedjem imunizacije zelo nedonošenih otrok (rojenih ≤ 28. tednom nosečnosti), zlasti tistih z anamnezo respiratorne nezrelosti, je treba upoštevati možnost apneje in potrebo po 48- do 72-urnem respiratornem nadzoru.
The potential risk of bleeding and haemostasis disorders
Potencialno tveganje krvavitve in motenj hemostaze.
The potential risk of infections: Daliresp should not be initiated, or treatment should be stopped, in patients with severe acute infectious diseases.
Potencialno tveganje za okužbe: zdravila Daliresp se ne sme uvajati oz. zdravljenje je treba prekiniti pri bolnikih z resnimi oblikami akutnih infekcijskih bolezni.
The potential risk of infections: Libertek should not be initiated, or treatment should be stopped, in patients with severe acute infectious diseases.
Potencialno tveganje za okužbe: zdravila Libertek se ne sme uvajati oz. zdravljenje je treba prekiniti pri bolnikih z resnimi oblikami akutnih infekcijskih bolezni.
The potential risk with the combination of AZA or 6-MP and Simponi should be carefully considered.
Možno tveganje kombinirane uporabe AZA ali 6-MP in zdravila Simponi je treba skrbno pretehtati.
The potential risk- to-benefit ratio should be carefully evaluated before considering vaccination in such cases.
V takih primerih je treba pred odločitvijo za cepljenje skrbno oceniti morebitno tveganje in korist.
The potential risks and benefits associated with co-administration of ledipasvir/sofosbuvir with Stribild should be considered, particularly in patients at increased risk of renal dysfunction.
Upoštevati je treba možna tveganja in koristi, povezane s sočasnim dajanjem ledipasvirja/sofosbuvirja in zdravila Stribild, še posebej pri bolnikih s povečanim tveganjem ledvične bolezni.
The potential risks and benefits associated with co-administration of ledipasvir/sofosbuvir with tenofovir disoproxil fumarate given in conjunction with a boosted HIV protease inhibitor (e.g. atazanavir or darunavir) should be considered, particularly in patients at increased risk of renal dysfunction.
Upoštevati je treba možna tveganja in koristi, povezane s sočasnim dajanjem ledipasvirja/sofosbuvirja in dizoproksiltenofovirijevega fumarata z okrepljenim zaviralcem proteaze HIV (npr. atazanvirjem ali darunavirjem), še posebej pri bolnikih s povečanim tveganjem ledvične odpovedi.
The potential risks and benefits associated with co-administration should be considered, particularly in patients at increased risk of renal dysfunction.
Upoštevati je treba razmerje med tveganjem in koristjo, povezano s sočasnim dajanjem, še posebej pri bolnikih s povečanim tveganjem za ledvično odpoved.
The potential risks if used in combination with other vasodilators which act on cGMP or cAMP
Potencialna tveganja, če se uporablja v kombinaciji z drugimi vazodilatatorji, ki delujejo na cGMP ali cAMP.
The potential toxicity of 28 days of repeated intravenous injections of florbetaben was tested in rats and dogs, and the NOAEL was found to be at least 20 times the maximum human dose.
Na podganah in psih so preskušali morebitno toksičnost z 28-dnevnim ponavljajočim se intravenskim injiciranjem florbetabena in določili, da je NOAEL vsaj 20-krat višji od najvišjega odmerka pri ljudeh.
the potentially life threatening condition, the lack of alternative treatment, hydroxocobalamin may be given to a pregnant woman.
morebitnega smrtno nevarnega stanja, pomanjkanja alternativnih zdravljenj, hidroksokobalamin lahko da nosečnici.
The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea.
Med opaženimi znaki in simptomi, ki so lahko medicinsko pomembni, so letargija, povišan krvni tlak, somnolenca, tahikardija, navzea, bruhanje in driska.
The potentiation of anticholinergic effects with anti- parkinson agents and tricyclic antidepressants may also occur if antimuscarinic agents are used concurrently with such medicinal products.
Če se antimuskarinska zdravila uporabljajo sočasno z antiparkinsonskimi zdravili in tricikličnimi antidepresivi, se lahko okrepijo tudi antiholinergični učinki slednjih zdravil.
The pouch and desiccant should be discarded.
Vrečko in sušilno sredstvo zavrzite.
The powder can also be applied onto the moistened gelatin sponge, which is immediately applied onto the bleeding surface.
Prašek se lahko nanese tudi na navlaženo želatinsko gobico, ki se takoj zatem položi na površino krvavitve.
The powder containing the active substance and the excipient bovine collagen has the appearance of a white to off- white granular powder; the carmellose powder is a yellowish white powder.
Prašek, ki vsebuje zdravilno učinkovino in pomožno snov goveji kolagen je bel do umazano bel granularni prašek; karmeloza je rumenkasto bel prašek.
The powder containing the excipient carmellose (carboxymethylcellulose) is yellowish white.
Prašek, ki vsebuje karmelozo (karboksimetilcelulozo), je rumenkasto bel.
The powder contains live attenuated (weakened) feline viruses: feline calicivirus (strain F9),viral rhinotracheitis virus (strain F2) and feline panleucopenia virus (strain LR 72).
Prašek vsebuje žive oslabljene mačje viruse: mačji kalicivirus (sev F9), mačji virusni rinotraheitis (sev F2) in virus mačje panlevkopenije (sev LR 72).
The powder contains sorbitol.
Prašek vsebuje sorbitol.
The powder contains the active substance sulesomab.
Prašek vsebuje zdravilno učinkovino sulesomab.
The powder contains:
rašek vsebuje
The powder for concentrate for solution for infusion has to be reconstituted with water for injections, diluted with 0.9% sodium chloride intravenous solution and then administered by intravenous infusion.
Prašek za koncentrat za raztopino za injiciranje rekonstituirajte z vodo za injekcije, razredčite z 0,9 % raztopino natrijevega klorida za intravensko uporabo in aplicirajte bolniku z intravensko infuzijo.
The powder for concentrate for solution for infusion is reconstituted with 10 mL of water for injections or sodium chloride 9 mg/mL (0.9%) solution for injection per vial; following reconstitution the vial should be shaken gently to dissolve the powder.
Prašek za koncentrat za raztopino za infundiranje je treba rekonstituirati z 10 ml vode za injekcije ali 0,9 % (9 mg/ml) raztopine natrijevega klorida za injiciranje na vialo; po rekonstituciji je treba vialo rahlo pretresti, da se prašek raztopi.
The powder for oral suspension is a pink to light pink powder in a single-use sachet.
Prašek za peroralno suspenzijo je rožnat do svetlorožnat prašek v vrečki za enkratno uporabo.
The powder in the capsules must only be inhaled using the inhaler included in the pack.
Prašek v kapsulah je le za inhalacijo z inhalatorjem, priloženim v pakiranju zdravila.
The powder in the vial appears as a white or slightly yellow powder.
Prašek v viali je bel ali rumenkast prašek.
The powder in Zerene capsules is coloured with an intense dark blue dye, to prevent it being given to someone without their knowledge.
Prašek v kapsulah Zerene je obarvan z intenzivnim temnomodrim barvilom, kar preprečuje, da bi posamezna oseba zdravilo prejela brez svoje vednosti.
The powder is a white to off white cake.
Prašek je bele do belkaste barve in je v strjeni obliki.
The powder is a white to off- white powder or cake.
Prašek je bel do belkast prašek ali pogača.
The powder is a white to off-white cake.
Prašek in vehikel za raztopino za injiciranje Prašek je bel do sivo bel z enakomernimi delci.
The powder is a white to off-white lyophilised pellet in a glass vial.
Prašek so bele do sivo bele liofilizirane pelete v stekleni viali.
The powder is contained in colourless glass vials (5 ml) with a stopper, sealed with a purple flip-off cap on the aluminium overseal.
Prašek je pakiran v brezbarvne viale (5 ml) z zamaškom, zaščitenim s prevleko iz aluminija, ki ima na sredini vijolično pretržno zaporko, ki se odstrani na poteg.
The powder is inhaled into the lungs using the inhaler provided in the pack.
Prašek se inhalira v pljuča z inhalatorjem, priloženim v pakiranju zdravila.
The powder is off-white to light tan.
Prašek je belkast do svetlorjav.
The powder is packaged in a 3 ml Type I glass vial sealed with a chlorobutyl rubber stopper and an aluminum seal with a plastic flip-off cap.
Prašek se nahaja v 3-mililitrski viali iz stekla tipa I s klorobutilnim gumijastim batom in aluminijastim pokrovčkom s plastičnim zamaškom.
The powder is then transferred into the corresponding gel bottle.
Prašek nato prenesite v ustrezno stekleničko z gelom.
The powder is white and the solvent is clear and colourless.
Prašek je bele barve, vehikel pa bister in brezbarven.
The powder is white to almost white; the solvent is a clear liquid.
Prašek je bel do belkast, vehikel pa je bistra tekočina.
The powder is white to off-white.
prašek in vehikel za raztopino za infundiranje Prašek je bel do sivo-bel.
The powder is white to off-white.
Prašek je bel do sivkastobel.
The powder may take up to 45 minutes to dissolve into solution.
Da se prašek raztopi, lahko traja do 45 minut.
The powder must be mixed with the solvent (liquid) and withdrawn from the vial under aseptic conditions.
Prašek je treba zmešati z vehiklom (tekočino) in ga pod aseptičnimi pogoji posesati iz viale.
The powder must be mixed with the solvent (liquid) and withdrawn from the vial under aseptic conditions.
Prašek je treba zmešati z vehiklom (tekočino) in raztopino pod aseptičnimi pogoji posesati iz viale.
The powder must be reconstituted and the resulting concentrate must then be immediately diluted further prior to use.
Prašek je potrebno rekonstituirati, dobljeni koncentrat pa je potrebno pred nadaljnjo uporabo takoj razredčiti.
The powder must be reconstituted with 20 ml of solvent (water for injections).
Prašek je treba rekonstituirati z 20 ml vehikla (vode za injekcije).
The powder must be reconstituted with water for injections (see instructions on reconstitution in section 6.6) and filtered during administration using an intravenous administration set with a suitable infusion filter (recommended pore size 5 micrometers (µm)).
Prašek je treba rekonstituirati z vodo za injekcije (glejte navodila za rekonstitucijo v poglavju 6.6) in med dajanjem filtrirati z intravenskim priborom, ki ima primeren infuzijski filter (priporočena velikost por 5 mikrometrov (µm)).
The powder should be dispersed in 40 ml of water per sachet prior to administration.
Prašek je treba pred uporabo raztopiti v 40 ml vode na vrečko.
The powder should be dispersed in 60 ml of water per sachet prior to administration.
Prašek je treba pred uporabo raztopiti v 60 ml vode na vrečico.
The powder should be dispersed in 60 ml of water per sachet prior to administration.
Prašek je treba pred uporabo raztopiti v 60 ml vode na vrečko.
The powder should be mixed in a glass of water and should be taken immediately after mixing during the meal.
Prašek zmešajte v kozarcu vode in vsebino popijte takoj po pripravi, med obrokom.
The powder should be reconstituted with 5.3 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, dextrose 50 mg/ml (5 %) solution for injection, or Lactated Ringer’s solution for injection to achieve a concentration of 10 mg/ml of tigecycline.
Prašek morate rekonstituirati s 5,3 ml 0,9-odstotne (9 mg/ml) raztopine natrijevega klorida za injiciranje, 5-odstotne (50 mg/ml) raztopine glukoze za injiciranje ali z raztopino Ringerjevega laktata za injiciranje, tako da dosežete koncentracijo tigeciklina 10 mg/ml.
The powder should be reconstituted with 5.3 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, dextrose 50 mg/ml (5 %) solution for injection, or Lactated Ringer’s solution for injection to achieve a concentration of 10 mg/ml of tigecycline.
Prašek morate rekonstituirati s 5,3 ml 9-odstotne (9 mg/ml) raztopine natrijevega klorida za injiciranje, 5-odstotne (50 mg/ml) raztopine glukoze za injiciranje ali z raztopino Ringerjevega laktata za injiciranje, tako da dosežete koncentracijo tigeciklina 10 mg/ml.
The powder vial contains 75 mg aztreonam (as lysine).
Viala s praškom vsebuje 75 mg aztreonama (kot lizin).
The powder vial must be opened by carefully tearing off the aluminium cap and removing the rubber stopper.
Vialo s praškom morate previdno odpreti, tako da odtrgate aluminijasto zaporko in odstranite gumijasti zamašek.
The PPE population consisted of individuals:
PPE populacija je vključevala posameznike, ki:
The PRAC concluded that the risk of osteonecrosis (or death of bone tissue) in the jaw remains very low, but has recommended a number of measures to minimise the risk.
Odbor PRAC je zaključil, da tveganje za osteonekrozo (ali odmrtje kostnega tkiva) v čeljusti ostaja zelo majhno, a je priporočil vrsto ukrepov za zmanjšanje tveganja.
The PRAC considered that based on evidence during post-marketing period that there is a confirmed causal association between aflibercept and the above mentioned hypersensitivity reactions.
Odbor PRAC meni, da glede na dokaze iz obdobja trženja, obstaja vzročna povezava med afliberceptom in zgoraj omenjenimi preobčutljivostnimi reakcijami.
The PRAC considered that based on evidence from case reports of viral reactivation, some serious, following treatment with thalidomide, particularly in patients previously infected with the herpes zoster or hepatitis B viruses (HBV), that there is a confirmed causal association between thalidomide and varicella-zoster virus and hepatitis B virus (HBV) reactivation.
PRAC je menil, da je na podlagi dokazov iz poročil o primerih virusne reaktivacije, od katerih so bili nekateri resni, po zdravljenju s talidomidom, posebno pri bolnikih, ki so bili predhodno okuženi z virusom herpes zoster ali hepatitisa B (HBV), potrjena vzročna povezava med talidomidom in reaktivacijo virusa varicella-zoster in virusa hepatitisa B (HBV).
The PRAC considered that based on evidence from cases of pulmonary hypertension, some fatal, reported following treatment with thalidomide that there is a confirmed causal association between thalidomide and pulmonary hypertension.
PRAC je menil, da je na podlagi dokazov iz poročil o primerih pljučne hipertenzije, ki je bila včasih smrtna, o katerih so poročali po zdravljenju s talidomidom, potrjena vzročna povezava med talidomidom in pljučno hipertenzijo.
The PRAC considered that the product information of aripiprazole should be updated to include the adverse event ‘Hiccups” in section 4.8 of the SmPC, since a contributory role of aripiprazole in the reported cases could not be ruled out.
Odbor PRAC meni, da je treba informacije o zdravilu aripiprazol posodobiti, tako da se v poglavje 4.8 povzetka glavnih značilnosti zdravila vključi neželeni učinek »kolcanje«, saj vpliva aripiprazola v poročanih primerih ni mogoče izključiti.
The PRAC considered the cases of dechallenge and rechallenge to be important causal relationship information that contributes to confirm the safety signal.
Odbor PRAC je mnenja, da so podatki o primerih navedenih odzivov na prekinitev oziroma ponovno uvedbo zdravljenja pomembni za oceno vzročne povezanosti in lahko prispevajo k potrditvi varnostnega signala.
The PRAC considers that no further risk minimization measures are necessary but the new data warrant an update of the warning so that is expanded to any other vascular elbow lesions occurred among children in order to better reflect and characterize skin lesions in the SmPC.
PRAC smatra, da nadaljnji ukrepi za zmanjševanje tveganja niso potrebni, vendar pa zahtevajo novi podatki posodobitev opozorila, ki mora biti razširjeno na vsako lezijo komolca, ki se pojavi pri otrocih, da bi lahko tako bolje opredelili in označili kožne lezije v SmPC-ju.
The PRAC is of the opinion that there is enough evidence leading to the conclusion that severe infections during teriflunomide treatment can result to sepsis.
Odbor PRAC je mnenja, da obstaja dovolj dokazov, ki vodijo do zaključka, da lahko hude okužbe med zdravljenjem s teriflunomidom vodijo v sepso.
The PRAC observed that teriflunomide could not be excluded from potential causal association in cases where time to onset, de-challenge/rechallenge information and discontinuation were available.
Odbor PRAC je ugotovil, da potencialne vzročnosti teriflunomida, v primerih, kjer so bili na voljo čas do pojava, informacije o prekinitv/ponovni uvedbi in ukinitvi zdravljenja s teriflunomidom, ni mogoče izključiti.
The PRAC recommended updating the product information to inform health professionals and the patients of the potential for these adverse events.
Odbor PRAC je priporočil posodobitev informacije o zdravilu za obveščanje zdravnikov in bolnikov o verjetnosti teh neželenih učinkov.
The PRAC recommends that Hepatitis B virus status should be established before initiating treatment with thalidomide.
PRAC priporoča, naj se status virusa hepatitisa B ugotovi pred začetkom zdravljenja s talidomidom.
The PRAC recommends that patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease prior to initiating and during thalidomide therapy.
PRAC priporoča ocenjevanje bolnikov glede znakov in simptomov osnovnih bolezni srca in pljuč pred začetkom zdravljenja s talidomidom in med njim.
The practice of Gliolan-fluorescence-guided surgery (including participation in at least one case using Gliolan-fluorescence-guided surgery in the operating room with on-site instructions on the use of the microscope or demonstration of a fluorescence-guided resection by video);
diferenciaciji intenzitete fluorescence, ohranjanju varne razdalje od elokventnih izrazitih območij, praktični izvedbi kirurgije, vodene s fluorescenco zdravila Gliolan (vključno s sodelovanjem pri vsaj enem primeru uporabe zdravila Gliolan pri kirurškem posegu, vodenim s fluorescenco v operacijski sobi, z navodili za uporabo mikroskopa in video-prikazom resekcije, vodene s fluorescenco);
The practice of Gliolan-fluorescence-guided surgery (including participation in at least one case using Gliolan-fluorescence-guided surgery in the operating room with on-site instructions on the use of the microscope or demonstration of a fluorescence-guided resection by video);
diferenciaciji intenzitete fluorescence, ohranjanju varne razdalje od elokventnih izrazitih območij. praktični izvedbi kirurgije, vodene s fluorescenco zdravila Gliolan (vključno s sodelovanjem pri vsaj enem primeru uporabe zdravila Gliolan pri kirurškem posegu, vodenim s fluorescenco v operacijski sobi, z navodili za uporabo mikroskopa in video- prikazom resekcije, vodene s fluorescenco);
The pre- filled pen can be used for several injections.
Napolnjen injekcijski peresnik lahko uporabite za več injekcij.
The pre- filled pen is used only once then thrown away.
Napolnjeni injekcijski peresnik se uporabi samo enkrat, potem pa se zavrže.
THE PRE-FILLED PEN
NAPOLNJEN INJEKCIJSKI PERESNIK
The pre-filled pen (FlexTouch) is for use by one person only.
Napolnjen injekcijski peresnik (FlexTouch) je namenjen uporabi ene same osebe.
The pre-filled pen can provide a dose of 2-160 units in one injection in steps of 2 units.
Napolnjen injekcijski peresnik lahko injicira 2-160 enot v eni injekciji, v korakih po 2 enoti.
The pre-filled pen contains 1 dose of Taltz.
Napolnjeni injekcijski peresnik vsebuje 1 odmerek zdravila Taltz.
The pre-filled pen contains either 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 or 500 micrograms of darbepoetin alfa.
Napolnjen injekcijski peresnik vsebuje 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 ali 500 mikrogramov darbepoetina alfa.
The pre-filled pen contains glass parts.
Napolnjeni peresnik vsebuje steklene dele.
The pre-filled pen delivers 1–80 units in steps of 1 unit.
Injekcijski peresnik omogoča aplikacijo 1 do 80 enot v korakih po 1 enoto.
The pre-filled pen has a safety cover that will protect you from needle sticks or loss of drug by accidental bumping or touching.
Napolnjeni injekcijski peresnik ima pokrovček, ki preprečuje, da bi se po nesreči zbodli z iglo ali da bi zaradi naključnega sunka ali dotika Varnostni Varnostni
The pre-filled pen has a safety cover that will protect you from needle sticks or loss of medicine by accidental bumping or touching.
Napolnjeni injekcijski peresnik ima varnostni pokrovček, ki preprečuje, da bi se po nesreči zbodli z iglo ali da bi zaradi naključnega sunka ali dotika prišlo do izgube zdravila.
The pre-filled pen has an expiration date printed on it; do not use the medicine after this date.
Na napolnjenem injekcijskem peresniku je odtisnjen rok uporabnosti; ne uporabljajte zdravila po tem datumu.
The pre-filled pen is designed to be used with NovoTwist or NovoFine injection needles up to a length of 8 mm and as thin as 32G.
Napolnjen injekcijski peresnik je namenjen za uporabo z injekcijskimi iglami NovoTwist ali NovoFine, dolžine do 8 mm in debeline 32G.
The pre-filled pen is designed to deliver the entire contents as a fixed dose.
Napolnjeni injekcijski peresnik je namenjen za injiciranje celotne vsebine kot fiksnega odmerka.
The pre-filled pen is for ONE-TIME USE ONLY.
Napolnjeni peresnik je namenjen SAMO ZA ENKRATNO UPORABO.
The pre-filled pen is for single-use only.
En peresnik je namenjen le za enkratno uporabo.
The pre-filled pen is now ready to use.
Napolnjen injekcijski peresnik je sedaj pripravljen za uporabo.
The pre-filled pen is ready for use and contains 0.2 mL of solution.
Napolnjen injekcijski peresnik je pripravljen za uporabo in vsebuje 0,2 ml raztopine.
The pre-filled pen is ready for use and contains 0.5 mL of solution.
Napolnjen injekcijski peresnik je pripravljen za uporabo in vsebuje 0,5 ml raztopine.
The pre-filled pen must not be refilled.
Napolnjenega injekcijskega peresnika se ne sme znova polniti.
The pre-filled pen must not be shaken.
Napolnjenega peresnika ne smete stresati.
The pre-filled pen should not be stored with the needle attached.
Napolnjenega injekcijskega peresnika ne shranjujte s pritrjeno iglo.
The pre-filled pens have to be used as recommended in these instructions for use (see section 6.6).
Napolnjene injekcijske peresnike uporabljajte kot je priporočeno v navodilih za ravnanje (glejte poglavje 6.6).
The pre-filled syrin
ravni rob bata
The pre-filled syringe cannula is inserted through the 50 ml syringe opening so that the cannula is immersed in the sodium chloride 9 mg/ml (0.9%) solution for injection (Figure 2).
Vstavite kanilo napolnjene injekcijske brizge skozi odprtino 50 ml brizge tako, da se kanila potopi v raztopino natrijevega klorida 9 mg/ml (0,9 %) za injiciranje (Slika 2).
The pre-filled syringe contains 1 dose of Taltz.
Napolnjena injekcijska brizga vsebuje 1 odmerek zdravila Taltz.
The pre-filled syringe contains more than the recommended dose of 0.5 mg.
Vsebina napolnjene injekcijske brizge presega priporočeni odmerek 0,5 mg.
The pre-filled syringe contains more than the recommended dose, therefore when preparing the injection, the doctor must expel the excess volume and ensure the injection of the correct dose.
Napolnjena injekcijska brizga vsebuje večji odmerek od priporočenega, zato mora zdravnik pri pripravi injekcije iztisniti odvečno količino in zagotoviti injiciranje ustreznega odmerka.
The pre-filled syringe contains water for injections and metacresol (see section 2, ‘Important information about some of the ingredients of Valtropin’).
Napolnjena injekcijska brizga vsebuje vodo za injekcije in metakrezol (glejte poglavje 2, "Pomembne informacije o nekaterih sestavinah zdravila Valtropin").